Key result
Lisinopril treatment in paediatric patients was well tolerated and produced mean reductions in systolic and diastolic blood pressure of 19 and 18 mmHg, respectively, after six months.
Why the study?
Does lisinopril reduce blood pressure and is it well tolerated in paediatric patients?
Observational (n=123)
No
Does lisinopril reduce blood pressure and is it well tolerated in paediatric patients?
Lisinopril is well tolerated and produces clinically significant blood pressure reductions in pediatric patients.
Supports lisinopril use in pediatric hypertension; hypothesis-generating and requires randomized confirmation.
OBJECTIVE: To investigate the antihypertensive efficacy, dosing, tolerability and effects on growth of lisinopril (off label-use) in paediatric patients during long-term treatment. DESIGN: We conducted a retrospective analysis of data from 123 patients treated with lisinopril in a paediatric nephrology clinic over a 9.3-year period. Patients were categorised by age group and predominant clinical diagnosis: hypertension (n=59), renal parenchymal disease (n=27), diabetes mellitus (n=33) and miscellaneous (n=4). RESULTS: The vast majority were Caucasian (93%) and boys (66%). Mean duration of treatment was 2.0 years. Age at start of treatment ranged from two months to 17.7 years. Mean lisinopril starting and final doses were 0.105 mg/kg/day for hypertensive patients and 0.108 mg/kg/day for patients with renal disease, respectively. The most common adverse event was hypotension (8.6% of the patients). Haematology and serum biochemistry profiles were unaffected by lisinopril. Growth was not different from data recorded by Belgian population studies. In 29 of the 47 hypertensive patients who received lisinopril monotherapy, comparing blood pressure (BP) at baseline and after six months treatment, mean reductions in systolic/diastolic BP were 19/18 mmHg. CONCLUSIONS: Lisinopril was well tolerated in paediatric patients. Doses of 0.1 mg/kg/day produced clinically significant BP reduction in hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Raes et al. (2007) conducted an observational in Hypertension, renal parenchymal disease, diabetes mellitus (n=123). Lisinopril vs. Baseline was evaluated on Reduction in systolic/diastolic blood pressure at six months (19/18 mmHg reduction). Lisinopril treatment in paediatric patients was well tolerated and produced mean reductions in systolic and diastolic blood pressure of 19 and 18 mmHg, respectively, after six months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: